Reply to M.C. Chamberlain

Affiliations

¹ The University of Texas MD Anderson Cancer Center, Houston, TX mrgilbert@mdanderson.org.
² Radiation Therapy Oncology Group Statistical Center, Philadelphia, PA.
³ The University of Texas MD Anderson Cancer Center; The University of Texas Health Science Center-School of Nursing, Houston, TX.
⁴ The University of Texas MD Anderson Cancer Center, Houston, TX.
⁵ University Hospital Zurich, Zurich, Switzerland.
⁶ Lausanne University Hospitals, Lausanne, Switzerland.
⁷ Emory University Winship Cancer Center, Atlanta, GA.
⁸ University of Maryland, Baltimore, MD.

Comment

Mark R Gilbert et al. J Clin Oncol. 2014.

. 2014 May 20;32(15):1634-5.

doi: 10.1200/JCO.2013.54.9717. Epub 2014 Apr 21.

¹ The University of Texas MD Anderson Cancer Center, Houston, TX mrgilbert@mdanderson.org.
² Radiation Therapy Oncology Group Statistical Center, Philadelphia, PA.
³ The University of Texas MD Anderson Cancer Center; The University of Texas Health Science Center-School of Nursing, Houston, TX.
⁴ The University of Texas MD Anderson Cancer Center, Houston, TX.
⁵ University Hospital Zurich, Zurich, Switzerland.
⁶ Lausanne University Hospitals, Lausanne, Switzerland.
⁷ Emory University Winship Cancer Center, Atlanta, GA.
⁸ University of Maryland, Baltimore, MD.

No abstract available

Comment on

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP. Gilbert MR, et al. J Clin Oncol. 2013 Nov 10;31(32):4085-91. doi: 10.1200/JCO.2013.49.6968. Epub 2013 Oct 7. J Clin Oncol. 2013. PMID: 24101040 Free PMC article. Clinical Trial.
Lessons learned from Radiation Therapy Oncology Group 0525 trial.
Chamberlain MC. Chamberlain MC. J Clin Oncol. 2014 May 20;32(15):1633-4. doi: 10.1200/JCO.2013.54.6226. Epub 2014 Apr 21. J Clin Oncol. 2014. PMID: 24752051 No abstract available.

1. Chamberlain MC. Lessons learned from Radiation Therapy Oncology Group 0525 trial. J Clin Oncol. 2014;32:1633–1634. - PubMed
1. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. J Clin Oncol. 2013;31:4085–4091. - PMC - PubMed
1. Armstrong TS, Wefel JS, Wang M, et al. Net clinical benefit analysis of Radiation Therapy Oncology Group 0525: A phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2013;31:4076–4084. - PMC - PubMed
1. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856) Br J Cancer. 1992;65:287–291. - PMC - PubMed
1. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007;25:3357–3361. - PubMed